E3 ubiquitin ligase components in GtoPdb v.2023.1
Elena Faccenda,Robert Layfield +1 more
TL;DR: The E3 ubiquitin ligases as discussed by the authors are a family of highly heterogeneous proteins and protein complexes that recruit ubiquin-loaded E2 enzymes to mediate transfer of the ubiquin molecule from the E2 to protein substrates.
read more
Abstract: Ubiquitination (a.k.a. ubiquitylation) is a protein post-translational modification that typically requires the sequential action of three enzymes: E1 (ubiquitin-activating enzymes), E2 (ubiquitin-conjugating enzymes), and E3 (ubiquitin ligases) [30]. Ubiquitination of proteins can target them for proteasomal degradation, or modulate cellular processes including cell cycle progression, transcriptional regulation, DNA repair and signal transduction. E3 ubiquitin ligases, of which there are >600 in humans, are a family of highly heterogeneous proteins and protein complexes that recruit ubiquitin-loaded E2 enzymes to mediate transfer of the ubiquitin molecule from the E2 to protein substrates. Target substrate specificity is determined by a substrate recognition subunit within the E3 complex. E3 ligases are being exploited as pharmacological targets to facilitate targeted protein degradation (TPD), as an alternative to small molecule inhibitors [3], through the development of proteolysis targeting chimeras (PROTACs) and molecular glues.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
References
The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation
TL;DR: A product of the mdm-2 oncogene forms a tight complex with the p53 protein, and the mDM-2oncogene can inhibit p53-mediated transactivation.
3.3K
Identification of a Primary Target of Thalidomide Teratogenicity
Takumi Ito,Hideki Ando,Takayuki Suzuki,Toshihiko Ogura,Kentaro Hotta,Yoshimasa Imamura,Yuki Yamaguchi,Hiroshi Handa +7 more
TL;DR: A basis for thalidomide teratogenicity is revealed and may contribute to the development of new thalidmide derivatives without teratogenic activity.
Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide
Eric S. Fischer,Kerstin Böhm,John R. Lydeard,Haidi Yang,Michael B. Stadler,Simone Cavadini,Jane Nagel,Fabrizio C. Serluca,Vincent Acker,Gondichatnahalli M. Lingaraju,Ritesh Bhanudasji Tichkule,Michael Schebesta,William C. Forrester,Markus Schirle,Ulrich Hassiepen,Johannes Ottl,Marc Hild,Rohan Eric John Beckwith,J. Wade Harper,Jeremy L. Jenkins,Nicolas H. Thomä +20 more
TL;DR: The studies suggest that IMiDs block endogenous substrates (MEIS2) from binding to CRL4CRBN while the ligase complex is recruiting IKZF1 or IKzF3 for degradation, which implies that small molecules can modulate an E3 ubiquitin ligase and thereby upregulate or downregulate the ubiquitination of proteins.
915
The dTAG system for immediate and target-specific protein degradation
Behnam Nabet,Justin M. Roberts,Dennis L. Buckley,Dennis L. Buckley,Joshiawa Paulk,Joshiawa Paulk,Shiva Dastjerdi,Annan Yang,Alan L. Leggett,Michael A. Erb,Matthew A. Lawlor,Amanda Souza,Amanda Souza,Thomas G. Scott,Sarah Vittori,Jennifer A. Perry,Jun Qi,Georg E. Winter,Georg E. Winter,Kwok-Kin Wong,Nathanael S. Gray,James E. Bradner,James E. Bradner +22 more
TL;DR: The dTAG system pairs potent heterobifunctional degraders and extensible tagging strategies to achieve immediate and reversible degradation of divergent proteins, facilitating biological investigation and drug target validation in cells and in mice.
856
Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.).
Anita Gandhi,Jian Kang,Courtney G. Havens,Thomas Conklin,Yuhong Ning,Lei Wu,Takumi Ito,Hideki Ando,Michelle Waldman,Anjan Thakurta,Anke Klippel,Hiroshi Handa,Thomas O. Daniel,Peter H. Schafer,Rajesh Chopra +14 more
TL;DR: This work presents a molecular model in which drug binding to cereblon results in the interaction of Ikaros and Aiolos to CRL4CRBN, leading to their ubiquitination, subsequent proteasomal degradation and T cell activation.
580